Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palatin

0.2310
+0.01105.00%
Post-market: 0.1950-0.0360-15.58%19:59 EDT
Volume:3.73M
Turnover:795.85K
Market Cap:6.50M
PE:-0.16
High:0.2310
Open:0.1910
Low:0.1910
Close:0.2200
Loading ...

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

PR Newswire
·
28 Mar

BRIEF-Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Reuters
·
25 Mar

Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now

Zacks
·
13 Mar

Q2 2025 Palatin Technologies Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Feb

Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
14 Feb

Palatin’s Earnings Call: Mixed Results and Strategic Moves

TIPRANKS
·
14 Feb

Palatin Technologies Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
14 Feb

Palatin price target lowered to $7 from $17 at H.C. Wainwright

TIPRANKS
·
14 Feb

Palatin reports Q2 EPS (12c) vs. (56c) last year

TIPRANKS
·
13 Feb

Palatin Techs Q2 2025 GAAP EPS $(0.12) Beats $(0.42) Estimate. Cash And Equivalents Of $3.4M

Benzinga
·
13 Feb

Palatin Technologies Q2 EPS USD -0.12

THOMSON REUTERS
·
13 Feb

BUZZ-Palatin Technologies down after launching stock sale

Reuters
·
12 Feb

BRIEF-Palatin Technologies Says Co To Sell Up To $6 Million In Common Stock

Reuters
·
12 Feb

Palatin Technologies Inc - on Feb 11, Co Enters Into Sales Agreement With a.g.p.

THOMSON REUTERS
·
12 Feb

Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS
·
07 Feb

Palatin Technologies Inc - to Issue Warrants for 4.688 Million Shares at $1.00 per Share

THOMSON REUTERS
·
07 Feb

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Palatin Technologies (PTN)

TIPRANKS
·
06 Feb

BRIEF-Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide

Reuters
·
06 Feb

Palatin Technologies Inc - Topline Data Results Expected Later This Quarter

THOMSON REUTERS
·
06 Feb